Objective:To investigate the effects of bevacizumab injection on immune function and drug safety in patients with non-small-cell lung cancer (NSCLC).Methods:A total of 80 NSCLC patients admitted to Liaocheng Second People′s Hospital from August 2018 to August 2020 were selected as study subjects. They were divided into the observation group and the control group by random number table method, each group with 40 cases. The control group received routine chemotherapy and the observation group received bevacizumab injection as adjuvant therapy on the bases of control group. Short-term efficacy, serum T lymphocyte subsets, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (b-FGF) levels and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate and disease control rate in the observation group were significantly higher than those in the control group: 77.5%(31/40) vs. 55.0%(22/40), 92.5%(37/40) vs. 75.0%(30/40), χ2 = 4.53, 4.50, P<0.05. After the treatment, the levels of CD 3+, CD 4+, CD 8+ and CD 4+/CD 8+ in the observation group were increased ( P<0.05), while those in the control group were decreased ( P<0.05), the levels of CD 3+, CD 4+, CD 8+ and CD 4+/CD 8+ in the observation group after treatment were higher than those in the control group ( P<0.05). After the treatment, the levels of serum VEGF and b-FGF in both groups were decreased ( P<0.05), and the above indicators in the observation group were significantly lower than those in the control group ( P<0.05). The rate of adverse reactions in two groups had no significant differences ( P>0.05). Conclusions:Bevacizumab injection is safe and effective in the treatment of NSCLC, which can significantly improve the immune function of patients and reduce their serum VEGF and b-FGF levels.